Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methylphenidate HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2016
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
Details : Aptensio XR (Methylphenidate HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Aptensio XR
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2016
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Details : PRC-063 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 21, 2015
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methylphenidate HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2015
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
PRC-063 in an ADULT Workplace Environment
Details : PRC-063 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 26, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
Details : PRC-063 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 20, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRC-063 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 15, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Purdue Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
Details : PRC-063 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 15, 2014
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Purdue Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PG101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of PG101 for Dry Eye Syndrome
Details : PG101 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2014
Lead Product(s) : PG101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methylphenidate HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2011
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
